---
title: "Axsome Therapeutics rises on settlement with Teva for depression drug"
date: "2025-02-10 20:51:02"
summary: "** Shares of drugmaker Axsome Therapeutics rise 13.5% to $119.99 premarket** Co says it has entered into a settlement agreement with Teva Pharmaceuticals , resolving all patent litigation related to AXSM's depression drug Auvelity ** Under terms of agreement, AXSM to grant Teva license to sell generic version of Auvelity..."
categories:
  - "Reuters"
lang:
  - "en"
translations:
  - "en"
tags:
  - "Reuters"
menu: ""
thumbnail: ""
lead: ""
comments: false
authorbox: false
pager: true
toc: false
mathjax: false
sidebar: "right"
widgets:
  - "search"
  - "recent"
  - "taglist"
---

\*\* Shares of drugmaker Axsome Therapeutics rise 13.5% to $119.99 premarket

\*\* Co says it has entered into a settlement agreement with Teva Pharmaceuticals , resolving all patent litigation related to AXSM's depression drug Auvelity

\*\* Under terms of agreement, AXSM to grant Teva license to sell generic version of Auvelity beginning on or after March 31, 2039, if pediatric exclusivity is granted for Auvelity

\*\* If no pediatric exclusivity is granted, AXSM to grant Teva license six months earlier - on or after September 30, 2038

\*\* "This outcome is better than our base case, which assumed exclusivity through 2037"- brokerage Truist Securities

\*\* Litigation resulted from regulatory submission by Teva to FDA seeking approval to market a generic version of Auvelity in the U.S. before expiration of applicable Axsome patents

\*\* Stock had risen 6.3% in 2024

[Reuters](https://www.tradingview.com/news/reuters.com,2025:newsml_L4N3P110M:0-axsome-therapeutics-rises-on-settlement-with-teva-for-depression-drug/)
